Effectiveness of proprotein convertase subtilisin/kexin‐9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic

BACKGROUND: Lipoprotein(a) (Lp[a]) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin‐9 monoclonal antibodies (PCSK9mAbs) can lower Lp(a) levels in clinical trials, but their effects in patients with elevated Lp(a) in clinical practice...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Anindita, Pang, Jing, Chan, Dick C., Barnett, Wendy, Woodward, Ann Marie, Vorster, Mary, Watts, Gerald F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207967/
https://www.ncbi.nlm.nih.gov/pubmed/33955565
http://dx.doi.org/10.1002/clc.23607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207967/
https://www.ncbi.nlm.nih.gov/pubmed/33955565
http://dx.doi.org/10.1002/clc.23607

Ejemplares similares